Home | Publications | Drug Delivery place holder
place holder place holder

Drug Delivery

The Global Drug Delivery Market

Research Trends and Market Outlook

Publication Date   May 2006
Publisher   Arrowhead
Product Type   Strategic Report
Pages   233
ISBN Number   not applicable
Product Code   ARR012
Ask a question about this product?

Price £990.00

approximately: $1,961 | €1,258

Summary


The drug delivery industry has in recent years become a key partner for pharmaceutical companies in their efforts to maximize the patent lives of successful products. Drug delivery companies not only stand to benefit from patent expiry by providing their reformulation services to pharmaceutical companies, but also by producing their own versions of branded products with improved delivery mechanisms. Thus, post-patent expiry sales can be switched from the ethical manufacturer to the drug delivery sector.

This report is an up-to-date guide that assesses the current state of the drug delivery industry and its application to both the pharmaceutical and biotech industries. While the sector is still dominated by oral technologies, drug delivery systems have expanded to include more novel devices such as needleless injectables, PEGylation platforms and microelectromechanical devices.

The expanding market for biotechnology and gene-based products, which by their very nature are difficult to administer, represents an emerging opportunity for drug delivery technologies. These technologies are first expected to come to market as reformulations of existing macromolecular therapies, such as insulin.

This report analyzes the markets for oral, inhalable, injectable, transmucosal, transdermal and niche drug delivery technologies as they apply to both biotech and traditional pharmacological compounds

Key Features of This Report:

  • A thorough overview of both marketed and emerging drug delivery technologies set to impact the global pharmaceutical market
  • Analysis of the opportunities and threats to the global drug delivery industry
  • Profiles of drug delivery companies along with key financial figures and technology/product portfolios
  • Market analysis and outlook for the leading drug delivery technologies, including oral, injectable, inhalable, transdermal, transmucosal and niche technologies
  • Profiles of key emerging drug delivery technologies and profiles of leading companies, by type of technology

Who Should Buy This Report:

  • Companies interested in understanding the wider opportunities and challenges in the drug delivery industry
  • Pharma/biotech companies wishing to identify potential drug delivery partners
  • Companies with a need for an expansive overview of the drug delivery market and the R&D trends that are driving the industry forward.

Content


  • 1 Introducing the Field of Drug Delivery
    • 1.1 The Value of Drug Delivery Systems
    • 1.2 Drug Delivery and Product Differentiation
    • 1.3 Drug Delivery and Patent Extension
    • 1.4 The Optimal Time for Reformulation
    • 1.5 Optimizing R&D Returns Through Drug Delivery
    • 1.6 Opportunities and Threats to the Drug Delivery Sector
      • 1.6.1 Opportunities for Growth in the Drug Delivery Sector
      • 1.6.2 Threats to Additional Growth in the Drug Delivery Sector
    • 1.7 Business Models of Drug Delivery Companies
  • 2 An Overview of Drug Delivery Technologies
    • 2.1 Oral Drug Delivery
      • 2.1.1 Controlled Release
      • 2.1.2 Sustained Release
      • 2.1.3 Chronomodulation
      • 2.1.4 Rapid Dissolving and Taste-masking Tablets
      • 2.1.5 Macromolecular Drug Delivery
    • 2.2 Inhalable Drug Delivery
      • 2.2.1 Nebulizers
      • 2.2.2 Metered Dose Inhalers (MDIs)
      • 2.2.3 Dry Powder Inhalers (DPIs)
      • 2.2.4 Limitations of Pulmonary Delivery Systems for Systemic Delivery
      • 2.2.5 Aqueous Systems
    • 2.3 Injectable Drug Delivery
      • 2.3.1 Sustained Release Injectable Systems
      • 2.3.2 Liposomal Systems
      • 2.3.3 Needleless Systems
    • 2.4 Transmucosal Drug Delivery
      • 2.4.1 Buccal Delivery
      • 2.4.2 Nasal
      • 2.4.3 Rectal
      • 2.4.4 Vaginal
    • 2.5 Transdermal Drug Delivery
      • 2.5.1 Passive Formulations
      • 2.5.2 Active Formulations
    • 2.6 Niche Technologies
      • 2.6.1 Topical Systems
      • 2.6.2 Gene Delivery
      • 2.6.3 Implantable Systems
      • 2.6.4 Drug Delivery Microchips
      • 2.6.5 Nanotechnology
  • 3 Drug Delivery Market Analysis
    • 3.1 Key Market Segments
      • 3.1.1 Oral Drug Delivery
        • 3.1.1.1 Sales of Products Utilizing Oral Drug Delivery Technology
        • 3.1.1.2 Key Therapeutic Areas for Oral Drug Delivery
        • 3.1.1.3 Key Oral Drug Delivery Products Impacting Global Market
        • 3.1.1.4 The Outlook for Oral Drug Delivery Technology
      • 3.1.2 Inhalable Drug Delivery
        • 3.1.2.1 Sales of Products Utilizing Inhalable Drug Delivery
        • 3.1.2.2 Key Therapeutic Areas for Inhalable Drug Delivery
        • 3.1.2.3 Key Inhalable Drug Delivery Products Impacting Global Market
        • 3.1.2.4 The Outlook for Inhalable Drug Delivery Technology
      • 3.1.3 Injectable Drug Delivery
        • 3.1.3.1 Sales of Products Utilizing Injectable Drug Delivery Technology
        • 3.1.3.2 Key Therapeutic Areas for Injectable Drug Delivery
        • 3.1.3.3 Key Injectable Drug Delivery Products Impacting Global Market
        • 3.1.3.4 The Outlook for Injectable Drug Delivery Technology
      • 3.1.4 Transmucosal Drug Delivery
        • 3.1.4.1 Sales of Products Utilizing Transmucosal Drug Delivery Technology
        • 3.1.4.2 Key Therapeutic Areas for Transmucosal Delivery
        • 3.1.4.3 Key Transmucosal Drug Delivery Products Impacting Global Market
        • 3.1.4.4 The Outlook for Transmucosal Drug Delivery Technology
      • 3.1.5 Transdermal Drug Delivery
        • 3.1.5.1 Sales of Products Utilizing Transdermal Drug Delivery Technology
        • 3.1.5.2 Key Therapeutic Areas for Transdermal Drug Delivery
        • 3.1.5.3 Key Transdermal Drug Delivery Products Impacting Global Market
        • 3.1.5.4 The Outlook for Transdermal Drug Delivery Technology
      • 3.1.6 Niche Drug Delivery Technologies
        • 3.1.6.1 Sales of Products Utilizing Niche Drug Delivery Technologies
        • 3.1.6.2 Key Niche Drug Delivery Technology Product Impacting Global Market
        • 3.1.6.3 The Outlook for Niche Drug Delivery Technologies
  • 4 Emerging Drug Delivery Technologies: Oral Drug Delivery
    • 4.1 Key Product Profiles
    • 4.2 Key Company Involvement in the Field of Oral Drug Delivery
      • 4.2.1 ALZA
      • 4.2.2 Biovail
      • 4.2.3 Cardinal Health
      • 4.2.4 Depomed
      • 4.2.5 Emisphere
      • 4.2.6 Ethypharm
      • 4.2.7 Penwest
  • 5 Emerging Drug Delivery Technologies: Inhalable Drug Delivery
    • 5.1 Key Product Profiles
    • 5.2 Key Company Involvement in the Field of Inhalable Drug Delivery
      • 5.2.1 3M
      • 5.2.2 Alkermes
      • 5.2.3 Aradigm
      • 5.2.4 Nektar
      • 5.2.5 SkyePharma
  • 6 Emerging Drug Delivery Technologies: Injectable Drug Delivery
    • 6.1 Key Product Profiles
    • 6.2 Key Company Involvement in the Field of Injectable Drug Delivery
      • 6.2.1 Alkermes
      • 6.2.2 ALZA
      • 6.2.3 Aradigm
      • 6.2.4 Enzon
      • 6.2.5 Ethypharm
      • 6.2.6 Macromed
      • 6.2.7 Nektar
      • 6.2.8 QLT
      • 6.2.9 SkyePharma
  • 7 Emerging Drug Delivery Technologies: Transmucosal Drug Delivery
    • 7.1 Key Company Involvement in the Field of Transmucosal Drug Delivery
      • 7.1.1 Generex
      • 7.1.2 Nastech
      • 7.1.3 Pherin
  • 8 Emerging Drug Delivery Technologies: Transdermal Drug Delivery
    • 8.1 Key Product Profiles
    • 8.2 Key Company Involvement in the Field of Transdermal Drug Delivery
      • 8.2.1 3M
      • 8.2.2 Altea Therapeutics
      • 8.2.3 ALZA
      • 8.2.4 Noven
  • 9 Emerging Drug Delivery Technologies: Niche Drug Delivery Technologies
    • 9.1 Key Product Profiles
    • 9.2 Key Company Involvement in Niche Drug Delivery Technologies
      • 9.2.1 ALZA
      • 9.2.2 Connetics
      • 9.2.3 Inovio
      • 9.2.4 MacroChem
      • 9.2.5 NexMed
      • 9.2.6 pSivida
      • 9.2.7 QLT
      • 9.2.8 SkyePharma
  • 10 Key Drug Delivery Company Profiles
    • 10.1 3M
    • 10.2 Alkermes
    • 10.3 Altea Therapeutics
    • 10.4 ALZA (Johnson & Johnson)
    • 10.5 Aradigm
    • 10.6 Bioject
    • 10.7 Biovail
    • 10.8 Cardinal Health
    • 10.9 Cima Labs (Cephalon)
    • 10.10 Connetics
    • 10.11 CyDex
    • 10.12 Delsite Biotechnologies (Carrington Laboratories)
    • 10.13 Depomed
    • 10.14 DOR BioPharma
    • 10.15 DURECT
    • 10.16 Emisphere
    • 10.17 Enzon
    • 10.18 Ethypharm
    • 10.19 Generex
    • 10.20 Inovio (formerly Genetronics)
    • 10.21 IVAX
    • 10.22 MacroChem
    • 10.23 MacroMed
    • 10.24 Nastech
    • 10.25 Nektar
    • 10.26 NexMed
    • 10.27 Noven
    • 10.28 Penwest
    • 10.29 Pherin Pharmaceuticals
    • 10.30 QLT
    • 10.31 SkyePharma
    • 10.32 Watson Pharmaceuticals
  • 11 Leading Pharmaceutical Companies Utilizing Drug Delivery Technologies
    • 11.1 Pfizer
    • 11.2 GlaxoSmithKline
    • 11.3 Sanofi-Aventis
    • 11.4 Merck
    • 11.5 Johnson & Johnson
    • 11.6 AstraZeneca
    • 11.7 Novartis
    • 11.8 Bristol-Myers Squibb
    • 11.9 Wyeth
    • 11.10 Abbott Labs
  • List of Tables
    • Table 2.1 Drugs Suitable or Unsuitable for Controlled Release
    • Table 2.2 Advantages and Disadvantages of Transdermal Delivery
    • Table 2.3 Worldwide Government Funding for Nanotechnology R&D ($ mn)
    • Table 3.1 Key Oral Drug Delivery Products, 2004-2005 ($ mn)
    • Table 3.2 Leading Oral Drug Delivery Companies 2005, Key Products and Sales 2005 ($ mn)
    • Table 3.3 Key Inhalable Drug Delivery Products, 2004-2005 ($ mn)
    • Table 3.4 Key Injectable Drug Delivery Products, 2004-2005 ($ mn)
    • Table 3.5 Leading Injectable Drug Delivery Companies 2005, Key Products and Sales 2005 ($ mn)
    • Table 3.6 Key Transmucosal Drug Delivery Products, 2004-2005 ($ mn)
    • Table 3.7 Key Transdermal Drug Delivery Products, 2004-2005 ($ mn)
    • Table 3.8 Key Topical Drug Delivery Products, 2004-2005
    • Table 3.9 Key Niche Drug Delivery Products, 2004-2005 ($ mn)
    • Table 4.1 Key Oral Drug Delivery R&D Pipeline Drugs, 2006
    • Table 5.1 Key Inhalable Drug Delivery R&D Pipeline Drugs, 2006
    • Table 6.1 Key Injectable Drug Delivery R&D Pipeline Drugs, 2006
    • Table 6.2 SkyePharma's Injectables Pipeline
    • Table 7.1 Key Transmucosal Drug Delivery R&D Pipeline Drugs, 2006
    • Table 8.1 Key Transdermal Drug Delivery R&D Pipeline Drugs, 2006
    • Table 9.1 Key Topical Drug Delivery R&D Pipeline Drugs, 2006
    • Table 9.2 Key Niche Drug Delivery R&D Pipeline Drugs, 2006
    • Table 10.1 3M Key Financials, 2003-2005
    • Table 10.2 3M Drug Delivery Portfolio, 2006
    • Table 10.3 Alkermes Key Financials, 2003-2005
    • Table 10.4 Alkermes Drug Delivery Portfolio, 2006
    • Table 10.5 Altea Therapeutics Drug Delivery Portfolio, 2006
    • Table 10.6 ALZA Drug Delivery Portfolio, 2006
    • Table 10.7 Aradigm Key Financials, 2003-2005
    • Table 10.8 Aradigm Drug Delivery Portfolio, 2006
    • Table 10.9 Bioject Key Financials, 2003-2005
    • Table 10.10 Bioject Drug Delivery Portfolio, 2006
    • Table 10.11 Biovail Key Financials, 2003-2005
    • Table 10.12 Biovail Drug Delivery Portfolio, 2006
    • Table 10.13 Cardinal Health Key Financials, 2003-2005
    • Table 10.14 Cardinal Health Drug Delivery Portfolio, 2006
    • Table 10.15 Cephalon Key Financials, 2003-2005
    • Table 10.16 CIMA Labs Drug Delivery Portfolio, 2006
    • Table 10.17 Connetics Key Financials, 2003-2005
    • Table 10.18 Connetics Drug Delivery Portfolio, 2006
    • Table 10.19 CyDex Drug Delivery Pipeline, 2006
    • Table 10.20 Carrington Laboratories Key Financials, 2003-2005
    • Table 10.21 Depomed Key Financials, 2003-2005
    • Table 10.22 Depomed Drug Delivery Portfolio, 2006
    • Table 10.23 DOR BioPharma Key Financials, 2003-2005
    • Table 10.24 DOR BioPharma Drug Delivery Portfolio, 2006
    • Table 10.25 DURECT Key Financials, 2003-2005
    • Table 10.26 Durect Drug Delivery Portfolio, 2006
    • Table 10.27 Emisphere Key Financials, 2003-2005
    • Table 10.28 Emisphere Drug Delivery Portfolio, 2006
    • Table 10.29 Enzon Key Financials, 2003-2005
    • Table 10.30 Enzon Drug Delivery Portfolio, 2006
    • Table 10.31 Ethypharm Drug Delivery Portfolio, 2006
    • Table 10.32 Generex Key Financials, 2003-2005
    • Table 10.33 Generex Drug Delivery Portfolio, 2006
    • Table 10.34 Inovio Key Financials, 2003-2005
    • Table 10.35 Inovio Drug Delivery Portfolio, 2006
    • Table 10.36 IVAX Key Financials, 2003-2005
    • Table 10.37 IVAX Drug Delivery Portfolio, 2006
    • Table 10.38 MacroChem Key Financials, 2003-2005
    • Table 10.39 MacroChem Drug Delivery Portfolio, 2006
    • Table 10.40 MacroMed Drug Delivery Portfolio, 2006
    • Table 10.41 Nastech Key Financials, 2003-2005
    • Table 10.42 Nastech Drug Delivery Portfolio, 2006
    • Table 10.43 Nektar Key Financials, 2003-2005
    • Table 10.44 Nektar Drug Delivery Portfolio, 2006
    • Table 10.45 NexMed Key Financials, 2003-2005
    • Table 10.46 NexMed Drug Delivery Portfolio, 2006
    • Table 10.47 Noven Key Financials, 2003-2005
    • Table 10.48 Noven Drug Delivery Portfolio, 2006
    • Table 10.49 Penwest Key Financials, 2003-2005
    • Table 10.50 Penwest Drug Delivery Portfolio, 2006
    • Table 10.51 Pherin Pharmaceuticals Drug Delivery Portfolio, 2006
    • Table 10.52 QLT Key Financials, 2003-2005
    • Table 10.53 QLT Drug Delivery Portfolio, 2006
    • Table 10.54 SkyePharma Key Financials, 2003-2005
    • Table 10.55 SkyePharma Drug Delivery Portfolio, 2006
    • Table 10.56 Watson Pharmaceuticals Key Financials, 2003-2005
    • Table 10.57 Watson Pharmaceuticals Drug Delivery Portfolio, 2006
    • Table 11.1 Pfizer Key Financials, 2004-2005
    • Table 11.2 Pfizer Drug Delivery Portfolio, 2004-2005
    • Table 11.3 GlaxoSmithKline Key Financials, 2004-2005
    • Table 11.4 GlaxoSmithKline Drug Delivery Portfolio, 2004-2005
    • Table 11.5 Sanofi-Aventis Key Financials, 2004-2005
    • Table 11.6 Sanofi-Aventis Drug Delivery Portfolio, 2004-2005
    • Table 11.7 Merck Key Financials, 2004-2005
    • Table 11.8 Merck Drug Delivery Portfolio, 2004-2005
    • Table 11.9 Johnson & Johnson Key Financials, 2004-2005
    • Table 11.10 Johnson & Johnson Drug Delivery Portfolio, 2004-2005
    • Table 11.11 AstraZeneca Key Financials, 2004-2005
    • Table 11.12 AstraZeneca Drug Delivery Portfolio, 2004-2005
    • Table 11.13 Novartis Key Financials, 2004-2005
    • Table 11.14 Novartis Drug Delivery Portfolio, 2004-2005
    • Table 11.15 Bristol-Myers Squibb Key Financials, 2004-2005
    • Table 11.16 Bristol-Myers Squibb Drug Delivery Portfolio, 2004-2005
    • Table 11.17 Wyeth Key Financials, 2004-2005
    • Table 11.18 Wyeth Drug Delivery Portfolio, 2004-2005
    • Table 11.19 Abbott Labs Key Financials, 2004-2005
    • Table 11.20 Abbott Labs Drug Delivery Portfolio, 2004-2005
  • List of Figures
    • Figure 1.1 Optimal Time for Reformulation
    • Figure 1.2 Growth Prospects in the Drug Delivery Sector
    • Figure 6.1 Advanced PEGylated Drug Molecules
    • Figure 9.1 Connetics' VeraFoam Clinical Study Results
  • List of Graphs
    • Graph 3.1 Top 5 Products Utilizing Oral Delivery, Global Sales 2005 ($ mn)
    • Graph 3.2 Leading Oral Drug Delivery Companies, Combined Key Product Values 2005 ($ mn)
    • Graph 3.3 Key Therapeutic Areas of Emphasis for Oral Drug Delivery, # of Key Marketed Products
    • Graph 3.4 Top 5 Products Utilizing Inhalable Delivery, Global Sales 2005 ($ mn)
    • Graph 3.5 Inhalable Drug Delivery Market Share, by Technology 2005 ($ mn)
    • Graph 3.6 Top 5 Products Utilizing Injectable Delivery, Global Sales 2005 ($ mn)
    • Graph 3.7 Leading Injectable Drug Delivery Companies, Combined Key Product Values 2005 ($ mn)
    • Graph 3.8 Top 5 Products Utilizing Transmucosal Delivery, Global Sales 2005 ($ mn)
    • Graph 3.9 Leading Developers of Transmucosal-Based Therapeutics 2005 ($ mn)
    • Graph 3.10 Leading Transdermal Drug Delivery Companies, by # of Products on Market
    • Graph 3.11 Key Therapeutic Areas of Emphasis for Transdermal Drug Delivery, # of Key Marketed Products
    • Graph 4.1 Leading Companies Active in Oral Drug Delivery Development
    • Graph 4.2 Leading Indications for Oral Drug Delivery Products in Development
    • Graph 5.1 Leading Companies Active in Inhalable Drug Delivery Development
    • Graph 6.1 Leading Companies Active in Injectable Drug Delivery Development
    • Graph 7.1 Leading Companies Active in Injectable Drug Delivery Development
    • Graph 8.1 Leading Companies Active in Transdermal Drug Delivery Development
    • Graph 9.1 Leading Companies Active in Niche/Topical Drug Delivery Development